Trastuzumab (Herclon®, Herceptin®) is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Trastuzumab has antitumor activity against HER2-positive human breast tumor cells in laboratory models and is active for the trea™ent of women with HER2-overexpressing breast cancers. This antibody was approved in 1998 for clinical use for HER2 overexpressing metastatic breast cancer. In HER2 overexpressing cells, trastuzumab markedly down-regulates HER2 expression by accelerating receptor endocytosis and degradation and inhibits cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes. BioSim™ Trastuzumab ELISA kit has been developed for specific quantification of Trastuzumab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Trastuzumab in human serum and plasma.
• Detection Range: 11 - 300 ng/ml
• Sensitivity: Quantitative limit: 11 ng/ml, Detection limit: 2 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
